Cargando…
Addressing the Elephant in the Immunotherapy Room: Effector T-Cell Priming versus Depletion of Regulatory T-Cells by Anti-CTLA-4 Therapy
SIMPLE SUMMARY: Immunotherapy has transformed the treatment of advanced cancers by leveraging patients’ immune system in attacking tumor cells. Cytotoxic T-lymphocyte Associated Protein 4 (CTLA-4) is an immune checkpoint molecule highly expressed on regulatory T-cells (Tregs) that suppresses the fun...
Autores principales: | Hong, Megan M Y, Maleki Vareki, Saman |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946681/ https://www.ncbi.nlm.nih.gov/pubmed/35326731 http://dx.doi.org/10.3390/cancers14061580 |
Ejemplares similares
-
Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy
por: Krishnamoorthy, Mithunah, et al.
Publicado: (2021) -
CTLA-4 in Regulatory T Cells for Cancer Immunotherapy
por: Sobhani, Navid, et al.
Publicado: (2021) -
Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?
por: Tang, Fei, et al.
Publicado: (2018) -
Imaging regulatory T cell dynamics and suppression of T cell priming mediated by CTLA4
por: Matheu, Melanie P., et al.
Publicado: (2015) -
High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors
por: Maleki Vareki, Saman
Publicado: (2018)